Teva's reaffirmation of its FY23 adjusted EPS guidance, which is in line with the consensus, indicates that the company's financial performance is on track. This could reassure investors and potentially stabilize the stock price in the short term. However, the actual impact will depend on other market factors and investor sentiment.